Daniel Bradbury

Daniel M. Bradbury has served as a member of the board of directors since September 2012, and as chairman of the board of directors since September 2014. Since June 2018, Mr. Bradbury has served as Chief Executive Officer of Equillium, Inc., a publicly-traded biotechnology company, where he also served as its President from March 2017 until June 2018. Mr. Bradbury is the founder of and has served as the managing member of, BioBrit, LLC, life sciences consulting and investment firm, since September 2012. Mr. Bradbury served as President, Chief Executive Officer, and director of Amylin Pharmaceuticals, Inc. from March 2007 until Amylin’s acquisition by Bristol-Myers Squibb Company in August 2012. Prior to Amylin, Mr. Bradbury worked in marketing and sales for ten years at SmithKline Beecham Pharmaceuticals. Mr. Bradbury serves on the board of directors of numerous private companies and two publicly traded companies, Equillium, Inc. and Intercept Pharmaceuticals, Inc. He previously served on the board of directors of the following publicly-traded companies: Corcept Therapeutics, Inc., from 2012 to 2019; Geron Corporation, from 2012 to 2019; and Illumina, Inc. from 2004 to 2017. Mr. Bradbury holds a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.